327
Participants
Start Date
October 31, 2007
Primary Completion Date
September 26, 2016
Study Completion Date
September 26, 2016
gemtuzumab ozogamycin
gemtuzumab ozogamycin = 6mg/m² during the induction course (Day 4) gemtuzumab ozogamycin = 6mg/m² during the first intensive consolidation course (Day 4)
CH Pays d'Aix, Aix
CHU Amiens, Amiens
CHRU Angers, Angers
CH Avignon, Avignon
Centre Hospitalier de la Côte Basque, Bayonne
CHU Hôpital Minjoz, Besançon
CHU Morvan, Brest
CHU Hôtel Dieu, Clermont-Ferrand
CH Louis Pasteur, Colmar
CHU du Bocage, Dijon
CHU Michallon, Grenoble
CHU Dupuytren, Limoges
Institut Paoli Calmette, Marseille
CH Metz Thionvile, Metz
CHU Lapeyronie, Montpellier
CH Muller, Mulhouse
CHU Hôtel Dieu, Nantes
CHU Carémeau, Nîmes
CH La Source, Orléans
Hopital Cochin (AP-HP), Paris
CHU du Haut Lévèque, Pessac
CHU Jean Bernard - La Milétrie, Poitiers
CHU Robert Debré, Reims
CHU Pontchaillou, Rennes
Institut de Cancérologie de la Loire, Saint-Etienne
CHU Hautepierre, Strasbourg
CHU Purpan, Toulouse
CHU Bretonneau, Tours
CHU Brabois, Vandœuvre-lès-Nancy
Collaborators (1)
Chugai Pharmaceutical
INDUSTRY
French Innovative Leukemia Organisation
OTHER
Nantes University Hospital
OTHER